A coalition of attorneys general is urging the US government to use its legal authority to increase the availability and lower the price of Gilead Sciences' COVID-19 treatment remdesivir, as reported in the National Post.
In a letter sent to US health agencies, the coalition led by Louisiana Attorney General Jeff Landry and California Attorney General Xavier Becerra urged the federal government to ensure Americans can afford and have reasonable access to sufficient supply of remdesivir during this pandemic.
Gilead has priced remdesivir at $2340 per patient for wealthier nations and said will charge US patients with commercial insurance $3120 per course, or $520 per vial.
The US signed a deal with Gilead in June for more than 500,000 courses of the treatment, making up most of the company's output through September.
To read more NewsPoints articles, click here.